ADHD

August 8th 2025

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

August 1st 2025

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

July 30th 2025

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

July 29th 2025

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.